Synthesis and Biological Evaluation of Coumarin Derivatives with Promising Anti-Cancer Activity: Computational Kinase Profiling and Molecular Modeling Analysis.

Elkotamy, Mahmoud S.; Abdelrahman, Mohamed A.; Eldehna, Wagdy M.; Abdel-Aziz, Hatem A.; Abou-Seri, Sahar M.

doi:10.21608/ejchem.2024.343991.10974

	Synthesis and Biological Evaluation of Coumarin Derivatives with Promising Anti-Cancer Activity: Computational Kinase Profiling and Molecular Modeling Analysis.
Egyptian Journal of Chemistry
Volume 68, Issue 8, August 2025, Page 181-197 PDF (1.64 MB)
Document Type: Original Article
DOI: 10.21608/ejchem.2024.343991.10974
View on SCiNiTO
Authors
Mahmoud S. Elkotamy ¹; Mohamed A. Abdelrahman¹; Wagdy M. Eldehna²; Hatem A. Abdel-Aziz ³; Sahar M. Abou-Seri⁴
¹Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City Cairo 11829, Egypt
²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, P.O. Box 33516, Egypt
³Department of Applied Organic Chemistry, National Research Center, Dokki, Cairo 12622, Egypt
⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
Abstract
The growing resistance and toxicity associated with current cancer treatments highlight the urgent need for novel therapeutic agents. In this study, we synthesized a series of pyrazolopyrimidine-coumarin derivatives (10a-d) and evaluated their anti-cancer activity using the NCI-60 cell line panel, representing nine cancer types. Among the compounds, 10c demonstrated the most potent activity, achieving a mean growth inhibition of 50% across the entire cell lines' panel. To investigate its mechanism of action, we performed molecular docking studies against 18 kinases, identifying JAK1 and CDK2 as primary potential targets with binding affinities comparable to the ligands co-crystallized with the PDB protein complexes. Pharmacokinetic and toxicity predictions using ADMETLab 3.0, OSIRIS Property Explorer, and ProTox-III confirmed compound 10c as a promising drug-like candidate. These findings position 10c as a potential lead compound for developing next-generation anti-cancer agents. Future efforts will focus on optimizing this scaffold to combat resistance and toxicity, particularly enhancing JAK1 and CDK2 inhibition. This study underscores the potential of coumarin-based derivatives in advancing cancer therapeutics.
Keywords
Coumarin; Pyrazolo[1,5-a]pyrimidine; Anticancer; Molecular docking


Statistics Article View: 619 PDF Download: 291